Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check18 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.6%
- Check25 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check61 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the detailed description of a clinical trial for nintedanib in treating systemic sclerosis associated interstitial lung disease (SSc-ILD), while adding a new EudraCT number and a revision number.SummaryDifference9%
Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.